Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 08:15 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

BURNABY, British Columbia, April 18, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
March 22, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days

BURNABY, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
March 01, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major...
February 22, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

BURNABY, British Columbia, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
February 08, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

BURNABY, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...
January 09, 2023 08:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101...
January 04, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

BURNABY, British Columbia, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at...
December 02, 2022 08:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Company Presents Additional Positive Data from Open Label Extension of Phase 2b ‘X-TOLE’ Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking...
November 30, 2022 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022

BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate...
November 09, 2022 16:30 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

BURNABY, British Columbia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s...